Siemens launches cancer assays for Dimension Vista systems

Siemens has announced the launch of a new range of cancer assays for use with the Dimension Vista Intelligent Lab Systems.

The science firm has received CE Mark accreditation for its LOCI CA 125II, CA 15-3 and CA 19-9 assays to be used with the device, allowing for the monitoring and management of patients with ovarian, breast and pancreatic cancer respectively.

This LOCI Advanced Chemiluminescence technology offers unlimited signal generation via an oxygen-channelling mechanism, reduced risk of errors and a smaller number of reaction steps.

It means the Dimension Vista system now offers a test menu of more than 120 assays, covering a wide array of disease monitoring and chemical analysis applications.

David Hickey, executive vice-president for the central laboratory and global research and development unit at Siemens Healthcare Diagnostics, said: "We are committed to providing a comprehensive portfolio of oncology assays that are trusted by cancer centres and institutions worldwide."

Last month, the company published a case study which highlights the cost-saving and efficiency benefits delivered by its VersaCell System sample management technology.